First, although we captured the most significant psoriasis loci known to date for calculation of the GRS, we did not include all known psoriasis loci.
Almost 90% of individuals with psoriasis have the most common form of the disease, known as psoriasis vulgaris or plaque psoriasis (Nestle et al., 2009).
Plaque psoriasis, also known as psoriasis vulgaris, is by far the most common type of psoriasis, accounting for 80% 90% of all psoriasis patients.
Inverse psoriasis (also known as flexural psoriasis) appears as smooth, inflamed patches of skin.
Psoriasis vulgaris (also known as chronic stationary psoriasis or plaque-like psoriasis) is the most common form and affects 85% 90% of people with psoriasis.
"See me to know that psoriasis is just something I have, and is not contagious".
These results suggest a significant correlation between the treatment-refractory hypertension and presence of psoriasis that is independent of other known cardiovascular risk factors.
Topical and oral administration of DMF (as a salt solution commercialized as Fumaderm) was indicated as early as year 1994 for the treatment of psoriasis before psoriasis was known to be an autoimmune disease or the molecular targets of DMF were identified (3).
Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs.
Deletion of LCE3B/C is a known risk factor for psoriasis (De Cid et al. 2009).
